

4 November 2025

**Aptamer Group plc**

("Aptamer", the "Company" or the "Group")

**Aptamer secures major repeat business with top 5 pharmaceutical partner**

*New contract value of up to £617,000*

*Contract value visibility for the current financial year of £1.75 million*

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has secured a new contract with a top five pharmaceutical company, with a value of up to £617,000.

This new contract is the third project with this pharmaceutical company and demonstrates a strong validation of the Optimiser® platform, which continues to deliver tools to support their key therapeutic developments. Having demonstrated superior performance of Optimiser® binders over traditional antibodies in the Group's previous project, the partner is now scaling the relationship with a multi-target programme.

Under the agreement, Aptamer will develop Optimiser® binders against three key drug targets and provide critical support for ELISA assay development. These tools will enable the partner to validate drug candidates and may also be used to analyse patient samples during clinical trials, potentially leading to clinical diagnostic development.

Importantly, Aptamer retains full intellectual property rights to all developed Optimisers, creating potential for future licensing revenues across each of the three targets as these binders prove their value in commercial applications.

Following a period of strong pipeline conversion during the first four months of the financial year, Aptamer has signed contract value of £1.75 million, which is a 46% increase compared to the £1.2 million reported at the same time last year. This gives the management team confidence in the delivery of continued growth for FY26, building on that achieved during FY25.

**Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said:** "This contract represents significant commercial validation and increasing traction of our Optimiser® technology platform. The decision by a top five pharmaceutical partner to commission this large-scale, multi-target programme follows the successful completion of a proof-of-concept project where we demonstrated the superior performance of our Optimisers compared to traditional antibodies and our ability to successfully deliver binders, to support our customers with their critical projects.

This means the Group now has signed contract value of £1.75 million for this financial year, with eight months of the financial year still remaining. As such, we are well-positioned to build on last year's performance and deliver sustained revenue growth. We continue to build a robust foundation of repeat business with leading pharmaceutical partners, converting our commercial pipeline into long-term value for shareholders."

**-Ends -**

**For further information, please contact:**

|  |                      |
|--|----------------------|
| <b>Aptamer Group plc</b>                                     | +44 (0) 1904 217 404 |
| Dr Arron Tolley, Chief Executive Officer                     |                      |
| <b>SPARK Advisory Partners Limited - Nominated Adviser</b>   | +44 (0) 20 3368 3550 |
| Andrew Emmott  |                      |
| <b>Turner Pope Investments (TPI) Limited - Broker</b>        | +44 (0) 20 3657 0050 |
| James Pope / Andrew Thacker                                  |                      |
| <b>Northstar Communications Limited - Investor Relations</b> | +44 (0) 113 730 3896 |
| Sarah Hollins  |                      |

**About Aptamer Group**

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimiser® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US 210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to  
<https://aptamergroup.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUPGRWGUPAPPW